Literature DB >> 20408053

Assessment of cell-free DNA with microvascular complication of type II diabetes mellitus, using PCR and ELISA.

Shereen A El Tarhouny1, Khaled M Hadhoud, Magdy M Ebrahem, Nashwa M Al Azizi.   

Abstract

In order to assess the potential biochemical markers in the development, diagnosis, and prognosis of diabetic patient with microvascular complication represented with retinopathy, we analyzed the levels of cell-free DNA by two different techniques. The levels of cell-free GAPDH assayed by quantitative PCR were significantly higher in the plasma samples of diabetic patients with and without diabetic retinopathy than in those of the control group; thus, it is a better biomarker than nucleosomes assayed by ELISA in patients with type 2 diabetes for the early detection of development of microvascular complications as retinopathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20408053     DOI: 10.1080/15257771003708298

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  7 in total

1.  Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis.

Authors:  Susana Coimbra; Susana Rocha; Henrique Nascimento; Maria João Valente; Cristina Catarino; Petronila Rocha-Pereira; Maria Sameiro-Faria; José Gerardo Oliveira; José Madureira; João Carlos Fernandes; Vasco Miranda; Luís Belo; Elsa Bronze-da-Rocha; Alice Santos-Silva
Journal:  Clin Kidney J       Date:  2020-08-24

Review 2.  Circulating Nucleic Acid-Based Biomarkers of Type 2 Diabetes.

Authors:  Felipe Padilla-Martinez; Gladys Wojciechowska; Lukasz Szczerbinski; Adam Kretowski
Journal:  Int J Mol Sci       Date:  2021-12-28       Impact factor: 5.923

Review 3.  Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management.

Authors:  Robert Stawski; Dariusz Nowak; Ewelina Perdas
Journal:  Viruses       Date:  2022-02-04       Impact factor: 5.048

4.  Liquid Biopsy in Type 2 Diabetes Mellitus Management: Building Specific Biosignatures via Machine Learning.

Authors:  Makrina Karaglani; Maria Panagopoulou; Christina Cheimonidi; Ioannis Tsamardinos; Efstratios Maltezos; Nikolaos Papanas; Dimitrios Papazoglou; George Mastorakos; Ekaterini Chatzaki
Journal:  J Clin Med       Date:  2022-02-17       Impact factor: 4.241

5.  Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients.

Authors:  Da Wun Jeong; Ju-Young Moon; Young-Wook Choi; Haena Moon; Kipyo Kim; Yu-Ho Lee; Se-Yeun Kim; Yang-Gyun Kim; Kyung-Hwan Jeong; Sang-Ho Lee
Journal:  Kidney Res Clin Pract       Date:  2015-11-12

6.  Maternal total cell-free DNA in preeclampsia and fetal growth restriction: Evidence of differences in maternal response to abnormal implantation.

Authors:  Tal Rafaeli-Yehudai; Majdi Imterat; Amos Douvdevani; Dan Tirosh; Neta Benshalom-Tirosh; Salvatore Andrea Mastrolia; Ruthy Beer-Weisel; Vered Klaitman; Reut Riff; Shirley Greenbaum; Alex Alioshin; Gal Rodavsky Hanegbi; Giuseppe Loverro; Mariana Rita Catalano; Offer Erez
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

7.  Serum cell-free DNA and progression of diabetic kidney disease: a prospective study.

Authors:  Xuan Li; RenZhi Hu; Ting Luo; Chuan Peng; Lilin Gong; Jinbo Hu; Shumin Yang; Qifu Li
Journal:  BMJ Open Diabetes Res Care       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.